Is Aquestive Therapeutics Stock a Good Investment?
Aquestive Therapeutics Investment Advice | AQST |
- Examine Aquestive Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Aquestive Therapeutics' leadership team and their track record. Good management can help Aquestive Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Aquestive Therapeutics' business and its evolving consumer preferences.
- Compare Aquestive Therapeutics' performance and market position to its competitors. Analyze how Aquestive Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Aquestive Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Aquestive Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Aquestive Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Aquestive Therapeutics is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Aquestive Therapeutics Stock
Researching Aquestive Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 52.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.45. Aquestive Therapeutics had not issued any dividends in recent years.
To determine if Aquestive Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Aquestive Therapeutics' research are outlined below:
| Aquestive Therapeutics generated a negative expected return over the last 90 days | |
| Aquestive Therapeutics has high historical volatility and very poor performance | |
| Aquestive Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Aquestive Therapeutics has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the previous year's revenue of 50.58 M. Net Loss for the year was (7.87 M) with profit before overhead, payroll, taxes, and interest of 40.87 M. | |
| Aquestive Therapeutics currently holds about 17.7 M in cash with (6.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33. | |
| Aquestive Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Aquestive Therapeutics to Present New Findings on Anaphylm at the 2025 AAAAI Annual Meeting |
Aquestive Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Aquestive Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aquestive Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Aquestive Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Aquestive Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-07 | 2023-06-30 | -0.12 | -0.1 | 0.02 | 16 | ||
2024-03-05 | 2023-12-31 | -0.08 | -0.11 | -0.03 | 37 | ||
2023-05-02 | 2023-03-31 | -0.19 | -0.12 | 0.07 | 36 | ||
2023-11-06 | 2023-09-30 | -0.11 | -0.03 | 0.08 | 72 | ||
2022-11-01 | 2022-09-30 | -0.31 | -0.23 | 0.08 | 25 | ||
2021-11-02 | 2021-09-30 | -0.45 | -0.37 | 0.08 | 17 | ||
2024-08-06 | 2024-06-30 | -0.12 | -0.03 | 0.09 | 75 | ||
2024-05-07 | 2024-03-31 | -0.08 | -0.17 | -0.09 | 112 |
Know Aquestive Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aquestive Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aquestive Therapeutics backward and forwards among themselves. Aquestive Therapeutics' institutional investor refers to the entity that pools money to purchase Aquestive Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Woodline Partners Lp | 2024-09-30 | 816.3 K | Amvescap Plc. | 2024-09-30 | 786.6 K | Essex Investment Management Company, Llc | 2024-09-30 | 707.1 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 671.5 K | Dafna Capital Management Llc | 2024-09-30 | 589.6 K | Northern Trust Corp | 2024-09-30 | 581.6 K | Bracebridge Capital, Llc | 2024-09-30 | 428.6 K | Everstar Asset Management Llc | 2024-09-30 | 400.1 K | Qube Research & Technologies | 2024-09-30 | 282.4 K | Bratton Capital Management, L.p. | 2024-09-30 | 9.8 M | Blackrock Inc | 2024-09-30 | 5.8 M |
Aquestive Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 302.71 M.Market Cap |
|
Aquestive Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.16) | (0.17) | |
| Return On Capital Employed | (0.44) | (0.47) | |
| Return On Assets | (0.16) | (0.17) | |
| Return On Equity | 0.07 | 0.06 |
Determining Aquestive Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Aquestive Therapeutics is a good buy. For example, gross profit margin measures Aquestive Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Aquestive Therapeutics' profitability and make more informed investment decisions.
Aquestive Therapeutics' Earnings Breakdown by Geography
Please note, the imprecision that can be found in Aquestive Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aquestive Therapeutics. Check Aquestive Therapeutics' Beneish M Score to see the likelihood of Aquestive Therapeutics' management manipulating its earnings.
Evaluate Aquestive Therapeutics' management efficiency
Aquestive Therapeutics has return on total asset (ROA) of (0.1557) % which means that it has lost $0.1557 on every $100 spent on assets. This is way below average. Aquestive Therapeutics' management efficiency ratios could be used to measure how well Aquestive Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2025. Return On Capital Employed is likely to drop to -0.47 in 2025. At this time, Aquestive Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 16.4 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 20 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.00) | (2.10) | |
| Tangible Book Value Per Share | (2.02) | (2.12) | |
| Enterprise Value Over EBITDA | 129.58 | 136.06 | |
| Price Book Value Ratio | (1.05) | (1.10) | |
| Enterprise Value Multiple | 129.58 | 136.06 | |
| Price Fair Value | (1.05) | (1.10) | |
| Enterprise Value | 153.2 M | 155.3 M |
Leadership at Aquestive Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 2.663 |
Basic technical analysis of Aquestive Stock
As of the 16th of February 2025, Aquestive Therapeutics shows the Mean Deviation of 3.08, risk adjusted performance of (0.11), and Standard Deviation of 4.14. Aquestive Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Aquestive Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aquestive Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aquestive Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aquestive Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aquestive Therapeutics' Outstanding Corporate Bonds
Aquestive Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aquestive Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aquestive bonds can be classified according to their maturity, which is the date when Aquestive Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Aquestive Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Aquestive Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (1.05) | |||
| Mean Deviation | 3.08 | |||
| Coefficient Of Variation | (620.92) | |||
| Standard Deviation | 4.14 | |||
| Variance | 17.16 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.68) | |||
| Total Risk Alpha | (0.68) | |||
| Treynor Ratio | (1.06) | |||
| Maximum Drawdown | 17.07 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 6.23 | |||
| Skewness | 0.6481 | |||
| Kurtosis | 1.66 |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (1.05) | |||
| Mean Deviation | 3.08 | |||
| Coefficient Of Variation | (620.92) | |||
| Standard Deviation | 4.14 | |||
| Variance | 17.16 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.68) | |||
| Total Risk Alpha | (0.68) | |||
| Treynor Ratio | (1.06) | |||
| Maximum Drawdown | 17.07 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 6.23 | |||
| Skewness | 0.6481 | |||
| Kurtosis | 1.66 |
Consider Aquestive Therapeutics' intraday indicators
Aquestive Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aquestive Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Aquestive Therapeutics Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 12th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 24th of January 2025 Other Reports | ViewVerify | |
F4 | 4th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Aquestive Stock media impact
Far too much social signal, news, headlines, and media speculation about Aquestive Therapeutics that are available to investors today. That information is available publicly through Aquestive media outlets and privately through word of mouth or via Aquestive internal channels. However, regardless of the origin, that massive amount of Aquestive data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aquestive Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aquestive Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aquestive Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aquestive Therapeutics alpha.
Aquestive Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Aquestive Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Aquestive Therapeutics Corporate Management
| Carl MD | Chief Officer | Profile | |
| Alexander Schobel | Chief Officer | Profile | |
| BSBA Esq | Sr Counsel | Profile | |
| Kenneth MD | Chief Officer | Profile | |
| Kenneth Marshall | Chief Officer | Profile | |
| Ernest Toth | Chief Officer | Profile | |
| Stephen Wargacki | Senior Development | Profile |
Already Invested in Aquestive Therapeutics?
The danger of trading Aquestive Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aquestive Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aquestive Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aquestive Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.